NMTR - 9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma (NMTR) has initiated its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with short bowel syndrome ((SBS)). The Phase 2 trial, known as the VIBRANT is expected to enroll approx. 22 patients. The trial protocol has achieved central IRB approval and will include 4 parallel treatment arms: vurolenatide 50 mg weekly, vurolenatide 50 mg every other week, vurolenatide 100 mg every other week and placebo.Total stool output will serve as the primary endpoint. Topline data is anticipated in Q4 2021, with a Phase 3 study expected to be initiated in the same quarter. Vurolenatide was previously evaluated in a Phase 1b/2a clinical trial evaluating the safety and tolerability of three escalating fixed doses of vurolenatide in 9 adults with SBS for 56 days

For further details see:

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome